Høgh, Julie
Hove-Skovsgaard, Malene
Gelpi, Marco
Jensen, Anne Marie Reimer
Gerstoft, Jan
Benfield, Thomas
Storgaard, Heidi
Nielsen, Susanne Dam
Funding for this research was provided by:
Novo Nordic Foundation
Gilead Sciences
Rigshospitalet Research Council
Article History
Received: 25 January 2022
Accepted: 18 May 2022
First Online: 28 May 2022
Declarations
:
: Ethical approval was obtained by the Regional Ethics Committee of Copenhagen (H-8-2014-004). The study was performed in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants.
: Not applicable.
: J.H reports grant from Novo Nordisk Foundation and Righospitalet Research Council. M.H.S, M.G, A.M.R.J and J.G reports no conflicts of interest. T.B reports grants from Novo Nordisk Foundation, grants from Simonsen Foundation, grants and personal fees from GSK, grants and personal fees from Pfizer, personal fees from Boehringer Ingelheim, grants and personal fees from Gilead, personal fees from MSD, personal fees from Astra Zeneca, personal fees from Janssen, grants from Lundbeck Foundation, grants from Kai Hansen Foundation, personal fees from Pentabase ApS, grants from Erik and Susanna Olesen’s Charitable Fund, outside the submitted work. H.S reports Steno Collaborative Grant, Novo Nordisk Foundation and advisory board activity for Novo Nordisk. S.D.N. has received unrestricted research grants from Novo Nordisk Foundation, Lundbeck Foundation, Rigshospitalet Research Council. Travelling grants from Gilead. Advisory board activity for Gilead and MSD, all unrelated to this manuscript. All other authors report no conflicts of interest.